CR20140213A - Preparación de liberación sostenida - Google Patents

Preparación de liberación sostenida

Info

Publication number
CR20140213A
CR20140213A CR20140213A CR20140213A CR20140213A CR 20140213 A CR20140213 A CR 20140213A CR 20140213 A CR20140213 A CR 20140213A CR 20140213 A CR20140213 A CR 20140213A CR 20140213 A CR20140213 A CR 20140213A
Authority
CR
Costa Rica
Prior art keywords
sustained release
release preparation
salt
active ingredient
provided containing
Prior art date
Application number
CR20140213A
Other languages
English (en)
Spanish (es)
Inventor
Yutaka Tanoue
Yusuke Murakawa
Yumiko Ishii
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20140213A publication Critical patent/CR20140213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CR20140213A 2011-10-21 2014-05-09 Preparación de liberación sostenida CR20140213A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21

Publications (1)

Publication Number Publication Date
CR20140213A true CR20140213A (es) 2014-06-18

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140213A CR20140213A (es) 2011-10-21 2014-05-09 Preparación de liberación sostenida

Country Status (30)

Country Link
US (1) US9907789B2 (cg-RX-API-DMAC7.html)
EP (1) EP2768487B1 (cg-RX-API-DMAC7.html)
JP (1) JP6093762B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140081826A (cg-RX-API-DMAC7.html)
CN (1) CN104039313A (cg-RX-API-DMAC7.html)
AP (1) AP2014007645A0 (cg-RX-API-DMAC7.html)
AR (1) AR088398A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012326976B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008744A2 (cg-RX-API-DMAC7.html)
CA (1) CA2852417A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014000992A1 (cg-RX-API-DMAC7.html)
CO (1) CO6960544A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140213A (cg-RX-API-DMAC7.html)
DO (1) DOP2014000077A (cg-RX-API-DMAC7.html)
EA (1) EA201490840A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14013328A (cg-RX-API-DMAC7.html)
IL (1) IL232114A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03169A (cg-RX-API-DMAC7.html)
MA (1) MA35717B1 (cg-RX-API-DMAC7.html)
MX (1) MX2014004679A (cg-RX-API-DMAC7.html)
NZ (1) NZ624275A (cg-RX-API-DMAC7.html)
PE (1) PE20141189A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500856A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201700121YA (cg-RX-API-DMAC7.html)
TN (1) TN2014000152A1 (cg-RX-API-DMAC7.html)
TW (1) TW201323018A (cg-RX-API-DMAC7.html)
UA (1) UA113858C2 (cg-RX-API-DMAC7.html)
UY (1) UY34403A (cg-RX-API-DMAC7.html)
WO (1) WO2013058409A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403103B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6093762B2 (ja) 2011-10-21 2017-03-08 武田薬品工業株式会社 徐放性製剤
US20150141517A1 (en) 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
ES2179829T3 (es) 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd Preparacion de hidrogel de liberacion prolongada.
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2003013609A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20050053677A (ko) 2002-09-20 2005-06-08 안드렉스 랩스 엘엘씨 비구아나이드와 티아졸리디네디온 유도체를 함유한 약제학적 투여형태
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (cg-RX-API-DMAC7.html) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
EP1607088B1 (en) 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
ZA200508932B (en) 2003-06-06 2007-03-28 Takeda Pharmaceutical Solid pharmaceutical preparation
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
MX2007002375A (es) 2004-08-31 2007-04-23 Pfizer Prod Inc Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad.
CA2623210A1 (en) 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
CN101410103B (zh) 2006-03-30 2013-04-10 日本脏器制药株式会社 固体药物制剂
WO2007126135A1 (en) 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Pharmaceutical composition of angiotensin ii antagonists with pioglitazone hcl
JP5467870B2 (ja) 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
EP2665479B1 (en) 2011-01-10 2019-06-26 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
JP6093762B2 (ja) 2011-10-21 2017-03-08 武田薬品工業株式会社 徐放性製剤
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
MA35717B1 (fr) 2014-12-01
PH12014500856A1 (en) 2014-05-19
EA201490840A1 (ru) 2014-08-29
JP6093762B2 (ja) 2017-03-08
KR20140081826A (ko) 2014-07-01
TW201323018A (zh) 2013-06-16
CL2014000992A1 (es) 2014-09-05
JP2014530802A (ja) 2014-11-20
SG2014012025A (en) 2014-06-27
EP2768487A1 (en) 2014-08-27
UY34403A (es) 2013-05-31
CO6960544A2 (es) 2014-05-30
MX2014004679A (es) 2014-08-01
AU2012326976A2 (en) 2014-06-12
DOP2014000077A (es) 2014-07-15
US20140248362A1 (en) 2014-09-04
BR112014008744A2 (pt) 2017-04-18
ECSP14013328A (es) 2014-05-31
TN2014000152A1 (en) 2015-09-30
NZ624275A (en) 2016-09-30
IN2014DN03169A (cg-RX-API-DMAC7.html) 2015-05-22
AU2012326976B2 (en) 2017-08-17
US9907789B2 (en) 2018-03-06
AP2014007645A0 (en) 2014-05-31
CA2852417A1 (en) 2013-04-25
ZA201403103B (en) 2015-08-26
UA113858C2 (uk) 2017-03-27
SG10201700121YA (en) 2017-03-30
AR088398A1 (es) 2014-05-28
AU2012326976A1 (en) 2014-05-29
WO2013058409A1 (en) 2013-04-25
PE20141189A1 (es) 2014-09-24
IL232114A0 (en) 2014-06-30
EP2768487B1 (en) 2020-06-03
CN104039313A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
CR20140213A (es) Preparación de liberación sostenida
CY2019031I1 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
CL2014002700A1 (es) Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
EP2317984A4 (en) ARTICLE FOR THE RELEASE OF AN ACTIVE SUBSTANCE
CR11583A (es) Arilpirrolinas insecticidas
UY34705A (es) Películas de capas múltiples capaces de liberar ingredientes activos por un período limitado de tiempo
EP2671604A4 (en) COMBINATION TANK / SYRINGE
CO6870038A2 (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
EP2688690A4 (en) ACTIVE ELECTROADHESION CLEANING
CO6801696A2 (es) Artículo absorbente que incluye una composición reguladora
CL2015000091A1 (es) Apósitos con una liberación prolongada de agentes activos.
EP2797414A4 (en) MICRO CAPSULE WITH FUNGICIDAL ACTIVE SUBSTANCE
PL3473191T3 (pl) Kaniula żywego dawcy
BR112014003027A2 (pt) formulação herbicida melhorada
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
ZA201208286B (en) Use of formulations having insecticidal activity
UY34222A (es) Partículas que comprenden un principio activo a base de poliacrilato
CO6970610A2 (es) Suspoemulsiones estables formadas por una pluralidad de ingredientes agrícolamente activos
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
CR20130520A (es) Composición herbicida que comprende flazasulfuron y metribuzina
CR20120521A (es) Combinaciones de principios activos
DK3251507T3 (da) Forbedrede insekticidformuleringer
UY34477A (es) Composición herbicida sinérgica que contiene penoxsulam y glufosinato de amonio